Boston Scientific Stock Forecast, Price & News

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Boston Scientific stock.
View analyst ratings for Boston Scientific or view top-rated stocks.

Wall Street analysts have given Boston Scientific a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Boston Scientific wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, April 28th 2021.
View our earnings forecast for Boston Scientific.

Boston Scientific will be holding an earnings conference call on Wednesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Boston Scientific Co. (NYSE:BSX) released its earnings results on Tuesday, February, 2nd. The medical equipment provider reported $0.23 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.31 by $0.08. The medical equipment provider earned $2.71 billion during the quarter, compared to analyst estimates of $2.83 billion. Boston Scientific had a net margin of 36.59% and a trailing twelve-month return on equity of 11.77%. The business's revenue for the quarter was down 6.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.46 earnings per share.
View Boston Scientific's earnings history.

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BSX stock has increased by 17.2% and is now trading at $39.67.
View which stocks have been most impacted by COVID-19.

Boston Scientific issued an update on its FY21 earnings guidance on Wednesday, February, 3rd. The company provided earnings per share (EPS) guidance of $1.50-1.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.62. The company issued revenue guidance of +13-19% to $11.2-11.8 billion, compared to the consensus revenue estimate of $11.61 billion.

20 equities research analysts have issued 1 year price targets for Boston Scientific's stock. Their forecasts range from $25.00 to $48.00. On average, they expect Boston Scientific's stock price to reach $43.20 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price.
View analysts' price targets for Boston Scientific or view top-rated stocks among Wall Street analysts.

947 employees have rated Boston Scientific CEO Michael F. Mahoney on Glassdoor.com. Michael F. Mahoney has an approval rating of 98% among Boston Scientific's employees. This puts Michael F. Mahoney in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Boston Scientific include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), STERIS (STE) and Varian Medical Systems (VAR).
View all of BSX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AT&T (T), CVS Health (CVS), The Walt Disney (DIS), Bank of America (BAC), Advanced Micro Devices (AMD), Visa (V) and salesforce.com (CRM).

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Boston Scientific's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Calamos Advisors LLC (0.07%), Gateway Investment Advisers LLC (0.06%), Royal London Asset Management Ltd. (0.04%), Welch & Forbes LLC (0.03%), State of Alaska Department of Revenue (0.02%) and Calamos Wealth Management LLC (0.01%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, Scott Olson, Wendy Carruthers, Williamson Scott and Xin Warren Wang.
View institutional ownership trends for Boston Scientific.

BSX stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, KMG Fiduciary Partners LLC, Calamos Wealth Management LLC, State of Alaska Department of Revenue, Pacer Advisors Inc., First Hawaiian Bank, Fulton Bank N.A., and Huntington National Bank. Company insiders that have sold Boston Scientific company stock in the last year include Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, Joseph Michael Fitzgerald, Maulik Nanavaty, Scott Olson, and Wendy Carruthers.
View insider buying and selling activity for Boston Scientific or view top insider-selling stocks.

BSX stock was acquired by a variety of institutional investors in the last quarter, including Union Bancaire Privee Asset Management LLC, Everence Capital Management Inc., First American Bank, Royal London Asset Management Ltd., AdvisorNet Financial Inc, RBA Wealth Management LLC, Collective Family Office LLC, and CHICAGO TRUST Co NA.
View insider buying and selling activity for Boston Scientific or or view top insider-buying stocks.

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BSX stock can currently be purchased for approximately $39.67.

Boston Scientific has a market capitalization of $56.35 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis.

Boston Scientific employs 36,000 workers across the globe.

The following companies are subsidiares of Boston Scientific: 34 Biomedical Merger Corp., 9357-1867 Quebec Inc., Acurate Industria e Comercio Ltda., Advanced Bionics, Advanced Stent Technologies, American Medical Systems, American Medical Systems Europe B.V., Apama Medical, Apama Medical Inc., Asthmatx, Atritech, Augmenix, Augmenix Inc., Augmenix K.K., BSC International Medical Trading (Shanghai) Co. Ltd., BSC Medical Device Technology (Shanghai) Co. Ltd., BTG, BTG Australasia Pty Ltd, BTG Europe B.V., BTG IM Holdings Ltd., BTG International (Holdings) Limited, BTG International Asia Limited, BTG International Canada Inc., BTG International Germany GmbH, BTG International Healthcare Inc., BTG International Healthcare LLC, BTG International Healthcare Limited, BTG International Inc., BTG International Limited, BTG Limited, BTG Management Services Limited, BTG Medikal Limited Sirketi, Bard Electrophysiology, Barosense, Biocompatibles Inc., Biocompatibles International Limited, Biocompatibles UK Limited, Boston Scientific (Malaysia) Sdn. Bhd., Boston Scientific (South Africa) Proprietary Limited, Boston Scientific (Thailand) Ltd., Boston Scientific (UK) Limited, Boston Scientific AG, Boston Scientific Argentina S.A., Boston Scientific Asia Pacific Pte. Ltd., Boston Scientific Benelux NV, Boston Scientific Canada Limited, Boston Scientific Ceska republika s.r.o., Boston Scientific Chile SpA, Boston Scientific Colombia Limitada, Boston Scientific Comercial de Costa Rica BSCR S.R.L., Boston Scientific Far East B.V., Boston Scientific Gesellschaft m.b.H., Boston Scientific Group plc, Boston Scientific Hellas S.A., Boston Scientific Hong Kong Limited, Boston Scientific Iberica S.A., Boston Scientific India Private Limited, Boston Scientific International B.V., Boston Scientific International Finance Limited, Boston Scientific International S.A., Boston Scientific Israel Ltd., Boston Scientific Japan K.K., Boston Scientific Korea Co. Ltd., Boston Scientific Lebanon SAL, Boston Scientific Limited, Boston Scientific Ltd., Boston Scientific Medical Device, Boston Scientific Medical Device Limited, Boston Scientific Medizintechnik GmbH, Boston Scientific Middle East FZ-LLC, Boston Scientific Middle East SAL, Boston Scientific Nederland B.V., Boston Scientific Neuromodulation Corporation, Boston Scientific New Zealand Limited, Boston Scientific Nordic AB, Boston Scientific Peru S.A.C., Boston Scientific Philippines Inc., Boston Scientific Polska Sp. z o.o., Boston Scientific Portugal - Dispositivos Medicos Lda, Boston Scientific Pty Ltd, Boston Scientific Romania S.R.L., Boston Scientific S.A.S., Boston Scientific S.p.A., Boston Scientific Scimed, Boston Scientific Scimed Inc., Boston Scientific Services Private Limited, Boston Scientific TIP Gerecleri Limited Sirketi, Boston Scientific Technology & Engineering Services Private Limited, Boston Scientific Uruguay S.A., Boston Scientific Vietnam Company Limited, Boston Scientific de Costa Rica S.R.L., Boston Scientific de Mexico S.A. de C.V., Boston Scientific del Caribe Inc., Boston Scientific do Brasil Ltda., Bravo Bidco Limited, BridgePoint Medical, Cameron Health, Cardiac Pacemakers Inc., Cardiac Pathways Corp, Catheter Innovations, Claret Medical, Claret Medical Inc., Cosman Medical, Cosman Medical LLC, CryoCor, Cryterion Medical, Cryterion Medical Inc., Cryterion Medical Ireland Limited, EKOS LLC, EMcision, EMcision International Inc., EP Technologies, EP Technologies Inc., Electron Acquisition Corporation, EndoChoice, EndoChoice Holdings Inc., EndoChoice Inc., EndoChoice Innovation Center Ltd., EndoChoice Israel Ltd., Endotex, Enteric Medical Technologies, Galil Medical Inc., Galil Medical Ltd., Galil Medical UK Limited, Guidant, Guidant Delaware Holding Corporation, Guidant Europe NV, Guidant Puerto Rico B.V., Hong Kong Medtech Trading Limited, Intelect Medical, Millipede, Millipede Inc., NXT Merger Corp., Notebook Merger Sub Ltd., Novate Medical Limited, NxThera, NxThera Inc., PT Boston Scientific Indonesia, PneumRx GmbH, PneumRx LLC, PneumRx Liimited, Protherics Medicines Development B.V., Protherics Medicines Development Limited, Protherics UK Limited, Provensis Limited, RMI Acquisition Corp., Remon Medical Technologies, Rhythmia Medical, Robert S. Smith M.D. Inc., Roxwood Medical Inc., SNS Merger Corp, Sadra Medical, Sadra Medical Inc., Securus Medical Group, Securus Medical Group Inc., Special K Merger Corp., StarMedTec, Stream Enterprises LLC, Symetis, Symetis SA, Target Therapeutics, Target Therapeutics Inc., The LumenR Tissue Retractor System, Veniti, Veniti Inc., VertiFlex, Vertiflex Inc., Vessix Vascular, Xlumena, Zuma Investment Pty Ltd, iogyn, nVision Medical, and nVision Medical Corporation.

Boston Scientific was founded in 1979.

The official website for Boston Scientific is www.bostonscientific.com.

Boston Scientific is headquartered at 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752.

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at (508) 683-4000 or via email at [email protected]